Entrada Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 22.51 M, actual EPS USD -1.47

PortAI

08-07 11:00

3 sourcesoutlets including Reuters

Brief Summary

Entrada Therapeutics reported a revenue of $22.51 million and an EPS of -$1.47 for the first half of 2025, with a net loss of $60.45 million.

Revenue: Entrada Therapeutics’ revenue for the first half of 2025 was $22.51 million, which shows a significant decrease from the $94.7 million in collaboration revenue reported in the same period last yearReuters+ 2.
Net Income/Loss: The company reported a net loss of $60.45 million, a considerable increase compared to a net loss of $43.1 million in the previous yearReuters.
Earnings Per Share (EPS): The EPS of -$1.47 reflects the company’s continued financial challenges.

Cash Position: With a cash reserve of $354 million as of June 30, 2025, Entrada has sufficient funds to support operations until the second quarter of 2027, despite the current lossesReuters.
Project Developments: The decline in revenue can be attributed to the substantial completion of the collaboration program associated with VX-670. However, the company plans to submit regulatory applications for ENTR-601-50 in the fourth quarter of 2025, and anticipates reporting data for ELEVATE-44-201 in the first half of 2026Reuters.

Comparison with Peers: Compared to other companies like AMD, which reported strong financial performance with significant revenue growth in the same period, Entrada’s results underscore the company’s challenges in maintaining revenue streams after key collaborations end.

Strategic Focus: Moving forward, Entrada Therapeutics is likely to focus on advancing its pipeline and securing new partnerships or agreements to compensate for the drop in collaboration revenue.
Financial Management: Effective cash management will be crucial for sustaining operations and supporting research and development efforts until projected milestones are achieved.

Event Track